Novo, Sanofi and Merck & Co all scored exits as the cancer drug developer, which had been spun off by Biox Biosciences, floated in a $101m offering.
Lava Therapeutics, a Netherlands-based immuno-oncology therapy developer that counts pharmaceutical companies Biox Biosciences, Novo, Sanofi and Merck & Co among its shareholders, has raised approximately $101m in a US initial public offering.
The offering consisted of 6.7 million shares priced at $15.00 each, in the middle of the $14 to $16 range set by the company. It floated on the Nasdaq Global Select Market and its shares closed at $12.70 yesterday.
Founded in 2016, Lava is working on bispecific…
